http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
코일과 클립을 선택적으로 적용해서 성공적으로 치료했던 다발성뇌동맥류 1례 : A case report
이덕구,김범태,황선철,임수빈,이세영,신원한 순천향의학연구소;Soonchunhyang Medical Research Institute 2004 Journal of Soonchunhyang Medical Science Vol.10 No.2
The author report a case of multiple cerebral aneurysm successfully treated with an appropricate selection of surgical clipping and coil embolization. A 64 years old female patient was admitted with stuporous consciousness. Initial 3D CT angiography showed diffuse subrarachnoid hemorrhage on the basal cisterns, saccular aneurysms on the terminal basilar artery and right middle cerebral artery(MCA). Converntional angiography confirmed the ruptured aneurysm was basilar one. Coil embolization was perfromed on the basilar aneurysm with 6 Guglielmi detachable coils(GDC) on the 3 days after ictus. Sugical clipping was done on the unruptured right MCA aneurysm on 10 days after ictus without any morbidity. Each treatment modalities can be appropriate indicated for the coiling or clipping aneurysms.
Hwang, Ji Sun,Kim, Gi-Cheon,Park, EunBee,Kim, Jung-Eun,Chae, Chang-Suk,Hwang, Won,Lee, Changhon,Hwang, Sung-Min,Wang, Hui Sun,Jun, Chang-Duk,Rudra, Dipayan,Im, Sin-Hyeog The American Association of Immunologists, Inc. 2015 JOURNAL OF IMMUNOLOGY Vol.194 No.4
<P>IL-31 is a key mediator of itching in atopic dermatitis (AD) and is preferentially produced by activated CD4<SUP>+</SUP> T cells and Th2 cells. Although pathophysiological functions of IL-31 have been suggested in diverse immune disorders, the molecular events underlying <I>IL-31</I> gene regulation are still unclear. In this study we identified the transcription start site and functional promoter involved in <I>IL-31</I> gene regulation in mouse CD4<SUP>+</SUP> T cells. TCR stimulation–dependent IL-31 expression was found to be closely linked with in vivo binding of NFAT1 and JunB to the <I>IL-31</I> promoter. Although NFAT1 alone enhanced <I>IL-31</I> promoter activity, it was further enhanced in the presence of JunB. Conversely, knockdown of either NFAT1 or JunB resulted in reduced <I>IL-31</I> expression. NFAT1-deficient CD4<SUP>+</SUP> T cells showed a significant defect in <I>IL-31</I> expression compared with wild-type CD4<SUP>+</SUP> T cells. In agreement with these findings, mice subjected to atopic conditions showed much higher levels of IL-31, which were closely correlated with a significant increase in the number of infiltrated NFAT1<SUP>+</SUP>CD4<SUP>+</SUP> T cells into the AD ears. Amelioration of AD progression by cyclosporin A treatment was well correlated with downregulation of IL-31 expressions in CD4<SUP>+</SUP> T cells and total ear residual cells. In summary, our results suggest a functional cooperation between NFAT1 and JunB in mediating <I>IL-31</I> gene expression in CD4<SUP>+</SUP> T cells and indicate that interference with this interaction or their activity has the potential of reducing IL-31–mediated AD symptoms.</P>
( Sun-ho Lee ),( Kiju Chang ),( Ki Seok Seo ),( Yun Kyung Cho ),( Eun Mi Song ),( Sung Wook Hwang ),( Dong-hoon Yang ),( Byong Duk Ye ),( Jeong-sik Byeon ),( Seung-jae Myung ),( Suk-kyun Yang ),( Sang 대한장연구학회 2020 Intestinal Research Vol.18 No.2
Background/Aims: The use of complementary and alternative medicine (CAM) is a global phenomenon, including inflammatory bowel disease (IBD) patients. We aimed to assess the change in prevalence and patterns of CAM use, and attitudes towards CAM over an 8-year time interval (2006 vs. 2014) among IBD patients in Korea. Methods: A total of 221 IBD patients (CD=142, UC=79) were asked to complete a questionnaire regarding CAM at two time points: at enrollment (2006) and 8 years later (2014/2015). Results: The proportion of patients ever using CAM increased significantly from 60.2% in 2006 to 79.6% in 2014 (P<0.001), while the proportion of current CAM users increased slightly (35.7% to 38.0%, P=0.635); 21.7% used CAM consistently at both time points. The proportion of patients who felt CAM was less effective (P<0.001) and more expensive (P=0.04) than conventional treatments increased over time. Also, the proportion among ever CAM users who perceived a positive effect from CAM significantly decreased in 2014 compared to 2006 (P=0.004). Higher education (adjusted odds ratio [aOR], 2.10), prior side effects to conventional therapies (aOR, 2.23), and prior use of corticosteroids (aOR, 2.51) were associated with CAM use. Interestingly, use of CAM before IBD diagnosis (aOR, 2.73) was significantly associated with consistent CAM use. Conclusions: Although the attitudes toward CAM have become less favorable, the majority of IBD patients have experienced CAM with an overall increase of current CAM users over time. Moreover, more than half of current CAM users used CAM consistently over time. (Intest Res 2020;18:192-199)
( Sun-ho Lee ),( Sung Wook Hwang ),( Sang Hyoung Park ),( Dong-hoon Yang ),( Jeong-sik Byeon ),( Seung-jae Myung ),( Suk-kyun Yang ),( Byong Duk Ye ) 대한장연구학회 2022 Intestinal Research Vol.20 No.2
Background/Aims: Fecal S100A12 (FS) and serum S100A12 (SS) have been reported as novel biomarkers that accurately reflect intestinal inflammation. We evaluated if FS and SS in comparison to fecal calprotectin (FC) are associated with poor future outcomes in clinically quiescent Crohn’s disease (CD) patients. Methods: We prospectively enrolled 49 CD patients in clinical remission (Crohn’s Disease Activity Index [CDAI] <150 for the past 6 months). Patients were followed for a median period of 4.4 years (interquartile range [IQR], 4.3-4.5). The following outcomes were evaluated: clinical relapse, CD-related hospitalization, step-up of medical treatment, and CD-related intestinal resection. Cox proportional-hazard regression model was constructed to assess the association of baseline markers with time-to-event outcomes. Results: The median levels of baseline FS, FC, and SS were 0.042 mg/kg (IQR, 0.005-0.179), 486.8 mg/kg (IQR, 203.5-886.8) and 1,398.2 ng/mL (IQR, 791.8-2,759.9), respectively. FS correlated with FC (r=0.689), erythrocyte sedimentation rate (r=0.524), C-reactive protein (r=0.499), and albumin (r=-0.446), but not with CDAI (r=0.045). Interestingly, increased FS (top quartile) was associated with a 4.9-fold increased rate of future CD-related hospitalization (P=0.009) and a 2.8-fold increased rate of step-up of medical treatment (P=0.032), whereas increased FC and SS were not. These findings remained significant after adjusting for age, sex, disease duration, current smoking, C-reactive protein, serum albumin, CDAI, and FC, individually. Conclusions: In this pilot study, increased FS and not FC or SS, was significantly associated with increased rates of future CD-related hospitalization and step-up of medical treatment among CD patients in clinical remission. (Intest Res 2022;20:203-212)
( Sun Hwa Lee ),( Dae Won Kim ),( Seon Ae Eom ),( Se Young Jun ),( Mee Young Park ),( Duk Soo Kim ),( Hyung Joo Kwon ),( Hyeok Yil Kwon ),( Kyu Hyung Han ),( Jin Seu Park ),( Hyun Sook Hwang ),( Won S 생화학분자생물학회 (구 한국생화학분자생물학회) 2012 BMB Reports Vol.45 No.6
We examined that the protective effects of ANX1 on 12-O-tetradecanoylphorbol- 13-acetate (TPA)-induced skin inflammation in animal models using a Tat-ANX1 protein. Topical application of the Tat-ANX1 protein markedly inhibited TPA- induced ear edema and expression levels of cyclooxygenase-2 (COX-2) as well as pro-inflammatory cytokines such as interleukin- 1 beta (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α). Also, application of Tat-ANX1 protein significantly inhibited nuclear translocation of nuclear factor-kappa B (NF-κB) and phosphorylation of p38 and extracellular signal- regulated kinase (ERK) mitogen-activated protein kinase (MAPK) in TPA-treated mice ears. The results indicate that Tat-ANX1 protein inhibits the inflammatory response by blocking NF-κB and MAPK activation in TPA-induced mice ears. Therefore, the Tat-ANX1 protein may be useful as a therapeutic agent against inflammatory skin diseases. [BMB Reports 2012; 45(6): 354-359]
Sun Young Cho,Hyun Duk Yang,Su Jin Hwang,Ji Young Yun,Joon Ki Kim,Beum Ho Jo,Ki Wha Chung,Byung Ok Choi 한국유전학회 2007 Genes & Genomics Vol.29 No.3
Moderately elevated plasma homocysteine level is associated with an increased risk of Alzheimer`s disease. Thymidylate synthase (TYMS) and 5,10-methylenetetrahydrofolate reductase (MTHFR) are involved in the homocysteine metabolic pathway. In this study, we tried to find the association between TYMS tandem repeat polymorphism and Alzheimer`s disease. We analyzed the genotype of the TYMS and MTHFR C677T polymorphisms in 68 Alzheimer`s patients and 413 healthy controls. The mean plasma homocysteine level was higher in Alzheimer`s disease patients than in healthy controls (p < 0.05). Those subjects who carried at least one TYMS 2R allele [2R(+)] showed an increased risk of Alzheimer`s disease (AOR, 2.09; 95%CI, 1.21-4.25). However, the MTHFR C677T polymorphism was not associated with an increased risk of Alzheimer`s disease. In the comparison of the combinations of polymorphisms, the risk of Alzheimer`s disease was highest in the subjects with the [2R(+)/T(+)] combined genotypes (AOR, 2.76; 95%CI, 1.30-6.71). In conclusion, particular genotype of TYMS tandem repeat polymorphism and combined genotypes of the TYMS tandem repeat and MTHFR C677T polymorphisms appeared to be predictive genetic biomarkers for the risk of Alzheimer`s disease.